Artículos por temáticas

Importance of the initial response to GPi deep brain stimulation in dystonia: A nine year quality of life study.

Tsuboi T, Jabarkheel Z, Foote KD, Okun MS, Wagle Shukla A.

Parkinsonism Relat Disord. 2019 Apr 30. pii: S1353-8020(19)30219-6. doi: 10.1016/j.parkreldis.2019.04.024. [Epub ahead of print]

Despite dystonia: natural history of delayed-onset pediatric secondary dystonia.

Krasovsky T, Bar O, Nachshon U, Livny A, Tsarfaty G, Brezner A, Landa J.

Brain Inj. 2019 May 5:1-7. doi: 10.1080/02699052.2019.1606452. [Epub ahead of print]

Treatment of cervical dystonia with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice.

Jochim A, Meindl T, Mantel T, Zwirner S, Zech M, Castrop F, Haslinger B.

J Neurol. 2019 May 2. doi: 10.1007/s00415-019-09349-2. [Epub ahead of print]

Major Contribution of Somatostatin-Expressing Interneurons and Cannabinoid Receptors to Increased GABA Synaptic Activity in the Striatum of Huntington's Disease Mice.

Holley SM, Galvan L, Kamdjou T, Dong A, Levine MS, Cepeda C.

Front Synaptic Neurosci. 2019 May 14;11:14. doi: 10.3389/fnsyn.2019.00014. eCollection 2019.

The effects of cognitive behavioral and mindfulness-based therapies on psychological distress in patients with multiple sclerosis, Parkinson's disease and Huntington's disease: Two meta-analyses.

Ghielen I, Rutten S, Boeschoten RE, Houniet-de Gier M, van Wegen EEH, van den Heuvel OA, Cuijpers P.

J Psychosom Res. 2019 Jul;122:43-51. doi: 10.1016/j.jpsychores.2019.05.001. Epub 2019 May 13. Review.

Genetic Counseling in Huntington's Disease: Potential New Challenges on Horizon?

Migliore S, Jankovic J, Squitieri F.

Front Neurol. 2019 Apr 30;10:453. doi: 10.3389/fneur.2019.00453. eCollection 2019.

Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease.

Wright GEB, Collins JA, Kay C, McDonald C, Dolzhenko E, Xia Q, Bečanović K, Drögemöller BI, Semaka A, Nguyen CM, Trost B, Richards F, Bijlsma EK, Squitieri F, Ross CJD, Scherer SW, Eberle MA, Yuen RKC

Am J Hum Genet. 2019 May 8. pii: S0002-9297(19)30153-3. doi: 10.1016/j.ajhg.2019.04.007. [Epub ahead of print]

EGF Treatment Improves Motor Behavior and Cortical GABAergic Function in the R6/2 Mouse Model of Huntington's Disease.

Marottoli FM, Priego M, Flores-Barrera E, Pisharody R, Zaldua S, Fan KD, Ekkurthi GK, Brady ST, Morfini GA, Tseng KY, Tai LM.

Mol Neurobiol. 2019 May 19. doi: 10.1007/s12035-019-1634-y. [Epub ahead of print]

Physical ACtivity and Exercise Outcomes in Huntington Disease (PACE-HD): Protocol for a 12-Month Trial Within Cohort Evaluation of a Physical Activity Intervention in People With Huntington Disease.

Drew CJG, Quinn L, Hamana K, Williams-Thomas R, Marsh L, Dimitropoulou P, Playle R, Griffin BA, Kelson M, Schubert R, Muratori L, Reilmann R, Rosser A, Busse M.

Phys Ther. 2019 May 17. pii: pzz075. doi: 10.1093/ptj/pzz075. [Epub ahead of print]

Alterations in Synaptic Function and Plasticity in Huntington Disease.

Smith-Dijak AI, Sepers MD, Raymond LA.

J Neurochem. 2019 May 16. doi: 10.1111/jnc.14723. [Epub ahead of print] Review.

The choice not to undergo genetic testing for Huntington disease: Results from the PHAROS study.

Anderson KE, Eberly S, Marder KS, Oakes D, Kayson E, Young A, Shoulson I; PHAROS Investigators..

Clin Genet. 2019 May 15. doi: 10.1111/cge.13529. [Epub ahead of print]

IKKβ slows Huntington's disease progression in R6/1 mice.

Ochaba J, Fote G, Kachemov M, Thein S, Yeung SY, Lau AL, Hernandez S, Lim RG, Casale M, Neel MJ, Monuki ES, Reidling J, Housman DE, Thompson LM, Steffan JS.

Proc Natl Acad Sci U S A. 2019 May 28;116(22):10952-10961. doi: 10.1073/pnas.1814246116. Epub 2019 May 14.

Targeting the neuronal calcium sensor DREAM with small-molecules for Huntington's disease treatment.

Lopez-Hurtado A, Peraza DA, Cercos P, Lagartera L, Gonzalez P, Dopazo XM, Herranz R, Gonzalez T, Martin-Martinez M, Mellström B, Naranjo JR, Valenzuela C, Gutierrez-Rodriguez M.

Sci Rep. 2019 May 13;9(1):7260. doi: 10.1038/s41598-019-43677-7.

Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington's disease by etanercept treatment.

Pido-Lopez J, Tanudjojo B, Farag S, Bondulich MK, Andre R, Tabrizi SJ, Bates GP.

Sci Rep. 2019 May 10;9(1):7202. doi: 10.1038/s41598-019-43627-3.

Rhes travels from cell to cell and transports Huntington disease protein via TNT-like protrusion.

Sharma M, Subramaniam S.

J Cell Biol. 2019 May 10. pii: jcb.201807068. doi: 10.1083/jcb.201807068. [Epub ahead of print]